Tinhofer Ingeborg, Niehr Franziska, Konschak Robert, Liebs Sandra, Munz Matthias, Stenzinger Albrecht, Weichert Wilko, Keilholz Ulrich, Budach Volker
Department of Radiooncology and Radiotherapy, Charité University Hospital Berlin, Translational Radiation Oncology Research Laboratory, Charitéplatz 1, 10117, Berlin, Germany.
German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) partner site, Heidelberg, Germany.
Radiat Oncol. 2015 Aug 28;10:183. doi: 10.1186/s13014-015-0481-x.
The introduction of next-generation sequencing (NGS) in the field of cancer research has boosted worldwide efforts of genome-wide personalized oncology aiming at identifying predictive biomarkers and novel actionable targets. Despite considerable progress in understanding the molecular biology of distinct cancer entities by the use of this revolutionary technology and despite contemporaneous innovations in drug development, translation of NGS findings into improved concepts for cancer treatment remains a challenge. The aim of this article is to describe shortly the NGS platforms for DNA sequencing and in more detail key achievements and unresolved hurdles. A special focus will be given on potential clinical applications of this innovative technique in the field of radiation oncology.
下一代测序(NGS)技术在癌症研究领域的引入推动了全球范围内全基因组个性化肿瘤学的发展,旨在识别预测性生物标志物和新的可操作靶点。尽管利用这一革命性技术在理解不同癌症实体的分子生物学方面取得了重大进展,且药物开发也同步创新,但将NGS研究结果转化为改进的癌症治疗理念仍然是一项挑战。本文旨在简要介绍用于DNA测序的NGS平台,并更详细地阐述关键成就和未解决的障碍。将特别关注这一创新技术在放射肿瘤学领域的潜在临床应用。